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Abstract
Purpose of Review Advances in coronary imaging techniques have revealed that there are important sex differences in the pattern
of ischemic heart disease. In this review, we aim to summarize our current knowledge and focus on the relation between a distinct
symptom presentation in women and their underlying type of coronary artery disease.
Recent Findings Women in the age group 40–70 years more often have non-obstructive coronary artery disease (CAD) and
coronary vasomotor disorders compared with the traditional obstructive CAD as seen in men. These differences in pathophys-
iology translate into another symptom presentation which we should rather call characteristic than atypical. Women at risk for
coronary vasomotor disorders often have co-morbidities and an enhanced pro-inflammatory state, which leads the way to the
appropriate diagnosis. Progress has been made with invasive testing to better discriminate between coronary spasm and micro-
vascular dysfunction. Treatment options are still limited and often disappointing for this heterogeneous patient population.
Summary Sex differences in ischemic heart disease truly exist and have been clearly defined over the past years. We should
therefore approach female patients according to this acquired knowledge. The challenge for the coming years will be a more
tailored diagnostic and therapeutic approach for symptomatic women at middle-age.
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Introduction
Female patients have historically been confusing for cardiol-
ogists. Being educated in treating obstructive coronary artery
disease (CAD), its different pattern of symptoms and athero-
sclerosis have surprised so many. In the early 1990s of the last
century, it was first assumed that women were discriminated
in diagnostics and treatment of CAD [1, 2]. In addition, it was
considered that gender issues in CADwere mainly driven by a
different way in symptom expression and not by biological
(sex) differences.
With the evolving knowledge gained by many percuta-
neous coronary intervention (PCI) research programs for
acute coronary syndrome (ACS) and elective PCI over the
past decades, we have learned that sex differences in
ischemic heart disease (IHD) truly exist. Obstructive
CAD occurs 7–10 years later in women than in men,
and women have fewer focal stenotic lesions at all ages
[3]. They have a lower plaque burden with less vascular
calcifications, a more diffuse pattern of atherosclerosis,
and more often soft plaques and erosive lesions [4–7].
Only a quarter of all included patients in PCI registries
are women, reflecting their different pattern of disease
[8••]. When having an ACS or an elective PCI, women
are older with a higher clustering of traditional CVD risk
factors. Coronary vasomotor disorders, such as coronary
artery spasm (CAS) and endothelial dysfunction, repre-
sent a major cause of ischemic cardiac symptoms in
middle-aged women.
Differences in underlying pathophysiology lead to a more
distinct presentation of angina symptoms and warrant a more
gender-sensitive, diagnostic, and therapeutic approach than
the usual male-oriented pathway. As appropriate diagnoses
are often lacking, this leads to an ongoing under-treatment
and results in adverse outcomes in the long run. It is therefore
not amazing that we observe a rise in the number of hospital-
izations for ACS in younger women, even under 55 years of
age [9•, 10•].
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Ischemia with Non-obstructive Coronary
Arteries
Women with symptoms of angina have twice as often ischemia
with non-obstructive coronary arteries (INOCA) compared
with men [3, 11]. Another often used term is NOCAD, mean-
ing non-obstructive coronary artery disease. The over-
emphasis of obstructive CAD over INOCA in our guidelines
is one of the main reasons that women are still less well treated
than men [12]. When coronary stenosis is less than 50% at
angiography, with a fractional flow reserve (FFR) ≥ 0.80, it is
considered to be not significant. Non-obstructive CAD is often
present in combination with coronary vasomotor disorders,
such as spasm and endothelial dysfunction of the larger and
smaller branches of the coronary tree [13, 14•]. In most symp-
tomatic patients, intravascular ultrasound (IVUS) shows some
signs of coronary atherosclerosis [15]. However, IVUS is not
routinely carried out in patients with INOCA, which may lead
to the misdiagnosis of “clean arteries” and subsequent under-
treatment of symptoms and risk factors. It has been demonstrat-
ed that INOCA is not a benign condition and that it has a higher
5-year event rate in symptomatic women compared with men,
especially when signs of ischemia are present [16, 17]. Women
with INOCA represent a very heterogeneous group, regarding
the extent of atherosclerosis, the presence of risk factors, symp-
toms, and functional impairment.
Fluctuating Symptoms in Women with INOCA
The clinical evaluation of symptoms of angina pectoris in
women is still considered along with the male standard of
obstructive CAD. The combination of INOCAwith vasomo-
tor disorders frequently occurs in young and middle-aged
women.Whereas typical symptoms of angina are more related
to epicardial stenoses, the combination of INOCAwith vaso-
motor dysfunction has other characteristics. Depending on the
involvement of coronary spasm and endothelial dysfunction,
chest painmay occur both at rest and during exercise and often
varies over time. Symptoms fluctuate within days and weeks
and may present in a crescendo/decrescendo pattern. The ma-
jority of patients feel unusually tired with a lack of energy. The
traditional risk factors such as hypertension and dyslipidemia
may serve as triggers for vascular dysfunction and coronary
spasm. Stress-related factors are equally important risk factors
and can also act as triggers for vascular dysfunction [18, 19•,
20]. Stressful circumstances and events often aggravate the
duration and intensity of symptoms [21].
Lack of patient awareness and gender differences in com-
munication styles frequently hamper the early recognition of
angina in women. In addition, women’s communication is
more likely to be emotional, subjective, polite, and self-
revealing with more concern and awareness for the feelings
of others. Men usually report their symptoms in a direct way,
while female patients ask more questions, present more and
diverse symptoms, and give more detailed histories of their
activities. This can be misleading to both female patients and
their doctors for the correct interpretation of their cardiac
symptoms. The diverse symptoms of stable angina in women
are depicted in Table 1.
Coronary Microvascular Dysfunction Type 1
Dominates in Women
In more than 60% of patients with INOCA, there is concom-
itant involvement of coronary microvascular dysfunction
(CMD) [22, 23]. Functional and/or structural abnormalities
in the coronary microcirculation result in impaired vasodila-
tation (endothelium-dependent and endothelium-independent
mechanisms) and an increased vasoconstriction level caused
by various stimuli [24, 25••]. Type 1 CMD with functional
impairment typically occurs in women between 40 and
70 years of age and is characterized by the absence of obstruc-
tive CAD or other structural heart diseases. Important contrib-
uting factors are obesity, smoking, and traditional cardiovas-
cular risk factors (dyslipidemia, hypertension, diabetes). In
addition, an enhanced inflammatory state such as in rheumatic
diseases and chronic intestinal bowel syndromes also predis-
pose for CMD [26••, 27]. It is increasingly acknowledged that
small vessel damage in the heart is a systemic phenomenon
and that these patients have generalized endothelial dysfunc-
tion leading to abnormal vascular reactivity [25••, 28••]. An
enhanced inflammatory state with signs of premature vascular
dysfunction may also be the reason that patients with type 1
CMD relatively frequently report a previous history of mi-
graine and severe hypertensive pregnancy disorders [29,
30•]. We have recently shown that women after preeclamptic
pregnancies have a twofold higher risk for identifiable coro-
nary calcium with CT (CAC score) compared with women
after normotensive pregnancies [31•]. It is therefore essential
to ask for these life events and co-morbidities when consider-
ing the diagnosis type 1 CMD (Fig. 1) [32].
Symptoms in patients with type 1 CMD overlap strongly
with INOCA and share their fluctuating and often unpredictable
character. Angina pectoris can occur both during exercise and
spontaneous in the evening or at night. Affected patients often
report to be extremely tired in the days after many activities.
Diagnosis and Management of Coronary
Vasomotor Disorders
The Coronary Vasomotion Disorders International Study
Group (COVADIS) has recently published two separate con-
sensus statements on vasospastic angina and microvascular
17 Page 2 of 5 Curr Cardiovasc Risk Rep (2019) 13: 17
angina as guidance for coronary vasomotor disorders [33, 34••].
As the diagnosis cannot be established based on symptoms
alone, additional non-invasive and invasive testing for ischemia
are recommended. With positron emission tomography (PET)
using ammonia, coronary flow reserve (CFR) can be measured.
A CFR< 2.5 is considered to be abnormal and a CFR < 2.0 is
associated with adverse cardiac outcomes [35]. Despite, in
many symptomatic patients, PET scans are not abnormal, pre-
sumably because vasospastic angina dominates over CMD.
ObstructiveCADcan be ruled outwithCTangiographywhen
a coronary angiography has not been done previously. The best
way to establish the diagnosis of vasomotor disorders is to per-
form invasive measures of the index of microvascular resistance
(IMR) and CFR and to perform vasoreactivity testing with ace-
tylcholine. This can be safely done by expert invasive cardiolo-
gists, using a standardized protocol [36, 37]. These invasive tests
are important to discriminate between vasospasm of the epicar-
dial coronary arteries and the coronary microvasculature.
Abnormal test results are associated with adverse outcomes [38].
Treatment of coronary vasomotor disorders starts with life-
style interventions and appropriate and adequate control of the
traditional risk factors. The use of anti-platelet therapy is not
routinely recommended, whereas statins are primarily indicat-
ed when lipid levels are elevated. Importantly, blood pressure
should be more strictly treated than what the guidelines ad-
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Fig. 1 Life course approach in
women with angina pectoris at
middle-age
Table 1 Classification of angina
with female-specific aspects (♀) Typical angina (definite) Meets 3 of the following characteristics:
• Oppressive substernal chest discomfort
• Provoked by exertion or emotional stress
• Relieved by rest and/or nitrates within minutes
♀ Squeezing, tight, chest discomfort
♀ Radiation to chest, jaw(s), left armpit and/or left arm, neck,
shoulders, and inter-scapular area
♀May last longer than minutes
♀ Crescendo /decrescendo character (spasm)
♀ Dyspnea, anxiety, mental stress-related
♀ Extreme tiredness, also often after angina episode
Atypical angina (probable) Meets 2 criteria
♀ Both typical and atypical symptoms in NOCAD
Non-anginal chest pain Lacks or meets only one characteristic criterion
♀ Beware of cardiac anxiety disorder
Adapted from: Montalescot G et al., 2013 ESC guidelines stable CAD
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relieve symptoms, but not at all times [12, 39]. Long-acting
nitrates may even aggravate symptoms. Depending on the
resting heart rate, high doses of calcium-antagonists can be
given, preferably diltiazem, even combined with low doses
selective beta-blockers. In patients with refractory angina,
non-traditional treatment options can be beneficial. These in-
clude xanthine derivates, ivabradine, nicorandil, and
ranolazine [12, 39, 40]. The use of postmenopausal hormone
replacement therapy has no additional beneficial effect in
women with CMD. As there is no standard treatment suited
for every patient, it may take time to find the best individual
options. Stress reduction programswith mindfulness and yoga
can be helpful in symptom reduction.
Conclusion
Advances in coronary imaging and the increased attention to
coronary vasomotor disorders over the past years are impor-
tant reasons why female patients are now more into the spot-
light. Progress has been made in better defining their charac-
teristic symptoms with important diagnostic and therapeutic
steps forward. However, many questions are still unresolved.
More fine-tuning in diagnosis and therapy is needed to better
serve each individual patient.
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